Diamide Antimicrobial Agents Targeting N-acetylglucosaminidase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibacterial agents face significant challenges due to antibiotic resistance, particularly with efflux pumps, target modification, and biofilm formation, leading to reduced efficacy and the need for novel compounds that can effectively inhibit bacterial infections with minimal resistance development.
Innovation Solution
Development of compounds of Formula (I), which include specific substituents and functional groups, designed to inhibit N-acetylglucosaminidase, an autolysin enzyme crucial for bacterial cell wall recycling, thereby targeting a key process in bacterial growth and division.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibacterial agents are used, then bacterial infections can be treated, but antibiotic resistance develops reducing efficacy
Solution Approach 1:
The invention divides the antibacterial mechanism into two distinct components: a peptidoglycan synthesis inhibitor ( targeting cell wall formation) and an autolysin inhibitor (blocking cell wall degradation). This segmentation allows simultaneous attack on both constructive and degradative pathways of cell wall metabolism, preventing bacteria from developing resistance through single-target adaptation while maintaining reliable antibacterial efficacy
Solution Approach 2:
The invention employs a composite therapeutic approach by combining two chemically distinct agents with different mechanisms of action into a single treatment regimen. The peptidoglycan synthesis inhibitor and autolysin inhibitor work synergistically, where the former prevents cell wall formation and the latter blocks protective degradation, creating a composite effect that overcomes resistance issues associated with single-agent therapy
2Reliability
If efflux pumps are utilized by bacteria, then antibiotics are pumped out reducing intracellular concentration, but this resistance mechanism limits drug efficacy
Solution Approach 1:
The autolysin inhibitor acts as an intermediary agent that blocks the protective degradation pathway mediated by autolysins. By inhibiting these enzymes that normally break down peptidoglycan, the compound prevents bacteria from utilizing their cell wall recycling system as a defense mechanism, thereby enhancing the accumulation and effectiveness of the peptidoglycan synthesis inhibitor despite efflux pump activity
3Reliability
If target modification is employed by bacteria, then the target structure is reprogrammed reducing antibiotic efficacy, but this requires precise molecular recognition
Solution Approach 1:
The peptidoglycan synthesis inhibitor performs preliminary action by blocking cell wall synthesis before the bacteria can initiate target modification or reprogramming responses. By preventing the formation of new peptidoglycan chains, the compound eliminates the substrate available for autolysin-mediated degradation and prevents bacteria from adapting their target structures, thereby maintaining high binding affinity and efficacy
Data Source
AI summary
This invention is directed to compounds of Formula (I)pharmaceutically acceptable salts, esters, and prodrugs thereof, to their preparation, to pharmaceutical compositions comprising compounds of Formula I, and to their uses as antimicrobial agents.